Episode 67
Biotech Hangout
00:00
Roy Van: A Company That's Different From Other Companies
Roy van: I think we have spilt a lot of ink over many years on Things that make us different from other companies. Right now, you know, I'd say like our current concentration is mostly in I and I So we have a late-stage portfolio one commercial medicine and psoriasis It's topical called vtama. We have an ATTO what a antibody that we acquired from Pfizer late last year That's gotten a lot of attention for a variety of reasons including Because of Merck's acquisition of Prometheus and so onWe have a portfolio of anti FCR and antibodies That we're working on developing that's I think A tremendously exciting targetA lot of really cool biology
Transcript
Play full episode
